Effect of Testosterone Treatment for Delayed Puberty in Duchenne Muscular Dystrophy

2020 ◽  
Vol 93 (2) ◽  
pp. 108-118 ◽  
Author(s):  
Samantha Lai-Ka Lee ◽  
Angelina Lim ◽  
Craig Munns ◽  
Peter J. Simm ◽  
Margaret Zacharin
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
C. L. Wood ◽  
T. D Cheetham ◽  
K. G Hollingsworth ◽  
M. Guglieri ◽  
Y. Ailins-Sahun ◽  
...  

2015 ◽  
Vol 46 (06) ◽  
pp. 371-376 ◽  
Author(s):  
Tim Cheetham ◽  
Michela Guglieri ◽  
Kate Bushby ◽  
Catherine Owen ◽  
Helen Johnstone ◽  
...  

2015 ◽  
Vol 101 (1) ◽  
pp. 101-106 ◽  
Author(s):  
Claire L Wood ◽  
Volker Straub ◽  
Michela Guglieri ◽  
Kate Bushby ◽  
Tim Cheetham

Children with Duchenne muscular dystrophy (DMD) are shorter than their healthy peers. The introduction of corticosteroid (CS) has beneficial effects on muscle function but slows growth further and is associated with pubertal delay. In contrast to CS usage in most children and adolescents, weaning glucocorticoid is not a key objective of management in DMD. As the outlook for these young people improves, one of the main challenges is to reduce or offset the detrimental effects of CS on growth and development. This is a review of the aetiology and prevalence of short stature and delayed puberty in DMD, a summary of the treatments available and suggestions for areas of further research.


2012 ◽  
Vol 43 (02) ◽  
Author(s):  
E Sarrazin ◽  
M von der Hagen ◽  
U Schara ◽  
K von Au ◽  
A Kaindl

Sign in / Sign up

Export Citation Format

Share Document